Modified Citrus Pectin for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Modified Citrus Pectin for Health & Longevity

Created on 08/26/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Modified citrus pectin is usually about five grams one to three times daily on empty stomach. Studies without a comparison group associated it with slower-rising prostate-cancer marker after prostate treatment and higher urinary lead, cadmium, arsenic. Randomized experiment did not change heart-scarring tests. Gas and loose stools are usual; potassium matters in advanced kidney disease. Not a demonstrated longevity therapy. (Full Review)

Protocol

Trial-style high dose
4.8–5 g three times daily
About 14.4–15 g/day mixed in liquid or as six 800 mg capsules per dose, on an empty stomach
Time of day
Empty stomach
Any clock time in trials; empty stomach matters more than clock time. Evening doses still need 2 hours after the last meal
Maintenance used by the commercial clinic
5 g once daily
After a high-dose block, with higher ongoing doses for active disease
Time to effect
Slowed PSA Rise After Local Prostate Therapy
6–12 months
Doubling-time changes assessed at 6–12 months after local prostate therapy
Increased Urinary Excretion of Lead, Cadmium, and Arsenic
1–6 days
Urinary metals moved within 1–6 days in the open pilot
Less Organ Fibrosis
No effect at 6 months
The six-month hypertension trial showed no fibrosis-marker effect

Benefits

Contraindications
  • Known citrus-peel or pectin allergy (anaphylaxis)
  • Bowel obstruction or high-grade stricture
  • Advanced chronic kidney disease with potassium restriction (eGFR below 45 mL/min/1.73 m² or potassium already above 5.2 mmol/L)
  • Unmonitored combination of high-dose powder with ACE inhibitor plus potassium-sparing diuretic in reduced filtration
    •
Key Interactions
  • Potassium-raising heart and blood-pressure drugs (ACE inhibitors such as lisinopril, ARBs such as losartan, potassium-sparing diuretics such as spironolactone)
  • Statins whose absorption pectin may blunt (lovastatin)
  • Oral tetracyclines (doxycycline) and digoxin
  • Over-the-counter oral iron and mineral antacids (ferrous sulfate, calcium carbonate)
  • Potassium-containing supplements and salt substitutes
  • Carotenoid and vitamin E supplements
  • Other binders (cholestyramine, charcoal, zeolite, high-dose alginate)
  • Other Gal-3-pathway or antifibrotic combinations (experimental small-molecule Gal-3 inhibitors, high-dose polyphenols used for fibrosis)
    •

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal cramping, gas, and loose stools
    •
  • Low: Reduced absorption of selected drugs and fat-soluble nutrients
    •
  • Speculative: High potassium in advanced kidney disease; citrus or pectin allergy
    •

Monitoring

Marker Target Why
Galectin-3 Track change from personal baseline; many functional clinics aim near or below ~13 ng/mL Surrogate for Gal-3 burden
Serum potassium 4.0–4.8 mmol/L Detects powder-related potassium load
eGFR (from creatinine) >90 mL/min/1.73 m² Kidney filtration sets potassium risk
PSA (men with prostate history) Track doubling time versus the person's pre-supplement slope Only repeated human outcome used in trials
Blood or 24-hour urine lead/cadmium/arsenic Fall in blood or rise in urine versus the person's baseline Confirms whether metal excretion occurred

Cadence: Baseline potassium and eGFR before high-dose use. Labs at 4 weeks, 12 weeks, then every 3–6 months at about 15 g/day, and every 6–12 months on 5 g maintenance. Recheck potassium 1–2 weeks after 15 g/day starts, and sooner if an ACE inhibitor, ARB, or potassium-sparing diuretic is added or eGFR is below 60. Repeat metal testing at 4–8 weeks if excretion is the goal. PSA follows existing biochemical-surveillance cadence.

Qualitative Assessment

  • Stool frequency and cramping in the first two weeks
  • Appetite and early satiety if mixed as a viscous drink
  • Urinary frequency and bone pain in men followed for biochemical relapse
  • Exercise tolerance and edema if the intended target is fibrosis biology
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.